AUPH logo

Aurinia Pharmaceuticals Inc. Stock Price

NasdaqGM:AUPH Community·US$1.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 23 Fair Values set on narratives written by author
Create a narrative

AUPH Share Price Performance

US$11.27
4.19 (59.18%)
31.5% undervalued intrinsic discount
US$16.46
Fair Value
US$11.27
4.19 (59.18%)
31.5% undervalued intrinsic discount
US$16.46
Fair Value
Price US$11.27
AnalystHighTarget US$16.46
AnalystConsensusTarget US$11.71
AnalystLowTarget US$9.00

AUPH Community Narratives

AnalystHighTarget·
Fair Value US$16.46 30.0% undervalued intrinsic discount

Aging Demographics And LUPKYNIS Uptake Will Expand Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$11.71 1.6% undervalued intrinsic discount

Pipeline Progress And ACR Updates Will Shape Future Opportunities

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AnalystLowTarget·
Fair Value US$9 28.1% overvalued intrinsic discount

Increasing Pricing Pressures And Limited Pipeline Will Weaken Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent AUPH News & Updates

Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)

Aug 06

Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality

May 19
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Strong Earnings Are Of Good Quality

Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 15
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Aurinia Pharmaceuticals Inc. Key Details

US$260.1m

Revenue

US$51.6m

Cost of Revenue

US$208.5m

Gross Profit

US$147.9m

Other Expenses

US$60.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.46
Gross Margin
80.16%
Net Profit Margin
23.31%
Debt/Equity Ratio
0%

Aurinia Pharmaceuticals Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

2 Risks
3 Rewards
View Full Analysis

About AUPH

Founded
1993
Employees
130
CEO
Peter Greenleaf
WebsiteView website
www.auriniapharma.com

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Market Insight

Header cover image

📈 Markets Break Records: Q3 2025 in Review, Q4 Outlook Ahead

Richard Bowman avatarRichard Bowman
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Last Week
✨Rare Earths: Tiny Market, Outsized Influence

✨Rare Earths: Tiny Market, Outsized Influence

Canadian Market Performance

  • 7 Days: -1.6%
  • 3 Months: 8.7%
  • 1 Year: 18.8%
  • Year to Date: 18.3%
Over the last 7 days, the market has dropped 1.6%, driven by a loss of 2.0% in the Financials sector. In the last year, the market is actually up 19%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›